Human herpesvirus 6 (HHV-6) is ubiquitous in the population and is a causative agent of febrile illness in children, particularly exanthem subitum (Yamanishi et al., 1988; Hall et al., 1994) . The virus has also been associated with disease in immunocompromised persons. In bone marrow transplant patients, HHV-6 has been linked to poor marrow engraftment, encephalitis and pneumonitis (Cone eta] ., 1993 b; Drobyski et a]., 1993 Drobyski et a]., , 1994 . The role of HHV-6 either as a co-factor in human immunodeficiency virus (HIV) disease progression or as an opportunistic infection in AIDS is unknown, although a number of mechanisms have been proposed (Griffiths, 1992; .
PCR provides a highly sensitive and specific technique with which to investigate disease associations. The detection of Author for correspondence: Vincent C. Eme W. Fax +44 171 830 2854. e-mail vincent@rfhsm.ac.uk HHV-6 DNA in serum or plasma by PCR has been used as a marker for active infection in blood (Huang et al., 1992; Secchiero et al., 1995a) . Since HHV-6 persists in the host following primary infection, PCR methods which can identify clinically relevant viral replication are required. One approach is to use quantitative PCR (QPCR) to determine the actual number of viral genomes (viral load). Although unable to differentiate active infection from latency, such a measurement is likely to vary between persistence in normal individuals and during primary infection or episodes of reactivation, and may be greater in patients who are immunocompromised. The importance of viral burden in disease pathogenesis has been demonstrated for a number of viruses including human cytomegalovirus (HCMV) and HIV in studies utilizing QPCR assays (Connor et al., 1993; Fox eta]., 1995) .
We have developed an HHV-6 QPCR based on methodology used previously in our laboratory for HCMV . This system relies on the co-amplification of a control sequence with the test sample thereby compensating for both the presence of inhibitors and well-to-well variation in the thermal cycler. The control sequence is identical to the wild-type sequence amplified except for specific base changes that create a restriction endonuclease site within the amplicon. The control and target sequences are differentiated in postamplification analysis by digestion of PCR products with the appropriate restriction endonuclease and separation by PAGE. The important advantage of our QPCR assay is that the kinetics of amplification of control and target sequences should not differ since both are similar in size, base composition, and possess identical primer binding sites. All but one HHV-6 QPCR assays reported previously have lacked the advantages of co-amplification-based QPCR. Cone et a]. (1993a, b) and Fairfax et aI. (1994) visually compared autoradiograph bands from the PCR products of the test sample with externally amplified known standards following hybridization with a radiolabelled probe. Limiting dilution of the sample prior to PCR has also been used to estimate viral burden in brain tissue (Challoner et al., 1995) . Only Secchiero et al. (1995 b ) employed the co-amplification of an internal standard containing identical primer binding sequences, similar percentage G+C composition, but a non-homologous sequence of a different size. 10 3 10 4 10 5 Actual input wild-type sequence copy number Fig. 1 . Characterization of the HHV-6 QPCR assay. Known copy numbers of the plasmid containing the wild-type target ranging from 25 to 50000 were co-amplified with known copy numbers of the plasmid containing the control sequence (ranging from 20 to 10000). Calculated wild-type copy numbers were plotted against actual input wild-type copy numbers. Each point represents the mean of triplicate determinations with standard error plotted as error bars,
We use nested PCR to detect HHV-6 in clinical samples using primers that have been described previously (Wakefield et al., 1992) . Primers A and B are the outer and C and D the inner primers. The construction of the control sequence utilized PCR site-directed mutagenesis. Mutational primers (E, 5' GCATTATATCCCGGGTTACTGTATCC 3'; F, 5' GGATA-CAGTAACCCGGGATATAATGC 3') complementary to each other were created that differ from the corresponding wild-type sequence by two bases (shown in bold) and generating a restriction site recognized by Sinai. The two mutational primers were used in separate PCRs. In one reaction primers A and F were employed and in another, primers B and E. Both reactions used DNA extracted from an HHV-6 variant B-infected cell line as template. The products were purified using the QIAquick PCR Purification Kit (QIAgen), mixed in equimolar amounts, denatured at 95 °C for i0 min, and reannealed by cooling to room temperature for 30 min. The annealed products were 3'-extended using Klenow polymerase and deoxynucleoside triphosphates and used as template in PCR utilizing 5'-phosphorylated primers A and B. The 223 bp product was purified, cloned into Ready-To-Go Sinai-cut pUC18 (Pharmacia Biotech) and base changes confirmed by digestion with Sinai and plasmid sequencing by the dideoxynucleotide chain termination method (Murphy & Kavanagh, 1988) .
To assess the utility of this control sequence in the QPCR, the wild-type sequence was cloned into pUC18 and a range of known copy numbers of the wild-type and control plasmids were co-amplified. One round of thermal cycling was performed using the outer primers where the input control copy number was > 1000. For reactions using < 1000 control sequence copies, a nested PCR was used limiting the second round to 18 cycles. Depending on whether a nested approach was used, 3 ng of either primer B or primer C radiolabelled with a2p was included. Following Sinai digestion of PCR products the radiolabelled fragment of the control sequence was 131 bp or 67 bp for outer or nested PCR respectively. Subsequent to PAGE, gels were autoradiographed, and the intensity of sample and control bands determined by scanning densitometry (Shimadzu CS-9001PC scanner). Wild-type plasmid ranging from 25 to 50000 copies was co-amplified with different control sequence copy numbers (20, 102, 10 a, 10 ~) in triplicate. The regression line was calculated by the method of least squares (Fig. 1) . Correlation analysis of the relationship between calculated and actual wild-type sequence copy numbers yielded a correlation co-efficient of 0"999 (P < 0"001). These results display the accuracy and suitability of the QPCR over this range of target copy number. The range of accurate quantification is the number of input control sequences-F 1 logarithm, i.e. with 100 control sequences, a test sample with between 10 to 1000 copies can be quantified accurately (data not shown). In each experiment a parallel PCR containing control sequence only was included to confirm complete digestion of amplified product.
We have used this QPCR to determine HHV-6 viral load in clinical material, firstly by utilizing blood samples taken from 25 healthy volunteers. Initially, quantities of DNA extracted from whole blood nucleated cells (Wizard Genomic DNA Purification Kit, Promega) ranging from 0" 1 lag to I"0 lag were tested by nested HHV-6 qualitative PCR and nine positive persons were found (Table l a ). Subsequently, PCR positive samples that were below the threshold of the QPCR assay (estimated at < 10 copies) were given an arbitrary viral load of 5 genome copies. The HHV-6 genome copy numbers in eight of the nine positive blood samples ranged between 5 to 32 genome copies/lag DNA, equivalent to a range of 34 to 214 copies/106 cells. Cone et al. (1993a) , using different QPCR methodology, calculated viral load in blood of healthy individuals to be between 4 to 4000 copies/106 cells. However, in that study, cell numbers were estimated by visually comparing the autoradiograph band of test samples against externally amplified known controls following amplification of a fl-globin sequence by PCR and hybridization with a radiolabelled probe. Also, Cone et al. (1993a) separated peripheral blood mononuclear cells from blood prior to DNA extraction which would enrich the cell population for those that harbour HHV-6.
The viral load in volunteer 1 (1'2 x 106 HHV-6 genomes per lag DNA) was considerably higher than the other volunteers in our study. The high viral burden was not a transient event since eight blood samples taken over a period of 10 months all contained similar levels of HHV-6 ( Table I b ). This demonstrates that a high HHV-6 viral load can persist in blood in an apparently healthy individual. High numbers of HHV-6 genomes have been described previously, using Southern blot analysis, in persons with lymphoma and immune disorders and 127; were associated with integration of HHV-6 sequences into chromosome 17 (Luppi et al., 1993; Torelli et al., 1995) . To assess the association between HHV-6 infection and disease it will be important to monitor viral load longitudinally in individuals under investigation. Secondly, HHV-6 QPCR was used to determine viral burden in multiple post-mortem tissue samples from seven patients with AIDS and three controls (two accidental sudden deaths, one heart attack). Qualitative PCR studies have shown that HHV-6 is widely disseminated in post-mortem samples from patients who died from AIDS and, to a lesser extent, in controls (Corbellino et al., 1993) . Active HHV-6 infection has been identified, using immunohistochemical methods, in lung, liver, lymph node, spleen and kidney from AIDS patients . More recently, active infection was also identified in central nervous system tissues from AIDS patients, but not controls (Knox & Carrigan, 1995) .
DNA was extracted from each tissue by a standard phenol-chloroform, ethanol precipitation method or with the Wizard Genomic DNA Purification Kit and i ~tg used per PCR reaction. The DNA from each tissue was co-amplified with three different control sequence copy numbers, i.e. 1000, 500, 100 and the HHV-6 genome copy number calculated from the PCR reaction closest to the point of equivalence. The results are shown in iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii iiii i ii i iii iiii iiiiiiiiiiiiiiiiiii Likewise, the majority of the tissues from AIDS patients (48/67) were qualitatively HHV-6 PCR positive with lymph node, spleen, lung, kidney, and liver frequently positive. However, the difference in HHV-6 median viral load for all tissues between the AIDS patients and controls was statistically significant (P--0"040) using the Mann-Whitney 'U' test (AIDS patients median of 56 copies/,g DNA, range 0-43 321; controls median of 10 copies/l~g DNA, range 0-423). When examining individual tissues, only the lung showed a statistically significant higher median viral load in AIDS patients compared to controls (P < 0"05 ; AIDS patients median of 165 copies/l~g DNA, range 56-449; controls median 44 copies/~g DNA, range 0-78).
The prevalence of HHV-6 and viral load has been reported to be low in the blood of HIV-infected persons with CD4 cell counts below 400 (median of 4 HHV-6 genomes/~g DNA) (Fairfax et al., 1994) . Thus, the picture in blood contrasts with our findings of widespread HHV-6 prevalence and a higher viral load (median 56 HHV-6 genome copies/l~g DNA) in post-mortem tissues and suggests that results in peripheral blood may underestimate the organ burden of HHV-6. reported differing levels of HHV-6 antigen positive cells, the majority of which were macrophages and lymphocytes, in AIDS post-mortem tissues. Interestingly, a number of tissues that we found to be PCR positive showed histological evidence of infiltrating mononuclear cells. The highest load was identified in the kidney tissue (AIDS2) although no histopathologica] abnormalities were noted. Most other tissues harboured considerably lower HHV-6 viral loads. The viral loads detected in lymph nodes were similar to those reported recently in a study that used QPCR to determine HHV-6 burden in lymph nodes from different origins including AIDS patients (Secchiero et al., 1995 b) . Cone et al. (1993 b) using QPCR found increased levels of HHV-6 DNA in lung tissue from bone marrow transplant patients which correlated with a decreased risk of fatal pneumonitis, increased severity of graft versus host disease and idiopathic pneumonitis. suggested that the high density of HHV-6-infected cells in the lung of one AIDS patient could be responsible for fatal pneumonitis. However, if HHV-6 interstitial pneumonitis is an immunopathological condition, as has been proposed for HCMV (Grundy et al., 1987) , it would require a functional immune system, which is defective in AIDS patients with low CD4 cell counts. This has to be taken into consideration when analysing the relationship of HHV-6 viral load and pneumonitis in such a patient group (Griffiths et al., 1994) . Although we found higher HHV-6 loads in the lungs of AIDS patients compared to controls, no cases of interstitial pneumonitis occurred.
In conclusion, we have developed a sensitive and accurate HHV-6 QPCR assay and shown that the majority of healthy individuals have low levels of HHV-6 in the blood. In addition, although HHV-6 infection was highly prevalent in organs of both AIDS patients and controls at death, there was a significantly higher HHV-6 load in the AIDS patients. Extension of these studies will enable the pathological consequences of HHV-6 infection to be assessed.
